BioXcel Therapeutics

$53.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.54 (-2.79%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BTAI and other stocks, options, and ETFs commission-free!

About BTAI

BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. The listed name for BTAI is BioXcel Therapeutics, Inc. Common Stock.

CEO
Vimal D. Mehta
Employees
24
Headquarters
New Haven, Connecticut
Founded
2017
Market Cap
1.30B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
470.29K
High Today
$56.86
Low Today
$51.53
Open Price
$54.45
Volume
393.48K
52 Week High
$71.50
52 Week Low
$13.77

BTAI Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

KOD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure